Cue Biopharma, Inc.
CUE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645460
In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Cue Biopharma, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 76 | 64 | −12 |
| Shares | 14.1M | 12.8M | −1.29M (−9.1%) |
| Value | $35.0M | $28.7M | −$6.38M (−18.2%) |
New holders (4)
Institutions that held Cue Biopharma, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Annandale Capital, LLC | 65,000 | $145.0K | 0.05% |
| Acadian Asset Management LLC | 63,234 | $139.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 32,677 | $73.0K | 0.00% |
| LPL Financial LLC | 10,570 | $24.0K | 0.00% |
Sold out (16)
Institutions that held Cue Biopharma, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 204,043 | $508.0K |
| Jump Financial, LLC | 35,296 | $88.0K |
| Bridgefront Capital, LLC | 19,968 | $50.0K |
| Ensign Peak Advisors, Inc | 17,960 | $45.0K |
| Engineers Gate Manager LP | 17,260 | $43.0K |
| Group One Trading, L.P. | 14,578 | $36.0K |
| Boothbay Fund Management, LLC | 12,366 | $31.0K |
| NinePointTwo Capital | 10,582 | $26.0K |
| Delphia (USA) Inc. | 10,126 | $25.0K |
| Legal & General Group Plc | 2,443 | $6.00K |
| Spire Wealth Management | 2,000 | $5.00K |
| New York State Common Retirement Fund | 274 | $1.00K |
| Citigroup Inc | 312 | $1.00K |
| Point72 Hong Kong Ltd | 234 | $1.00K |
| FMR LLC | 10 | $0 |
| Credit Suisse AG | 16 | $0 |